Smart investments, healthy returns

Capital Cell is the world’s leading alternative investment platform for early-stage biotech and life science companies. Selected by experts, backed by visionaries, we give you the chance to shape the future of health, one investment at a time. 

Performance to date

127
Rounds
Completed

112M€
Total amount
invested

3,04x
Multiple on
Capital

47
remaining days
Target
€1.000.000
Invested
60.2%

Robopedics

flag

ROBOPEDICS offers an alternative to wheelchairs for people with severe disabilities due to stroke

36
remaining days
Target
€2.150.000
Invested
115.2%

Aspivix

flag

Aspivix introduces a non-invasive alternative to the cervical tenaculum, improving accessibility to effective contraception

68
remaining days
Target
€500.000
Invested
62.7%

24Genetics

flag

The combination of Genetics and Artificial Intelligence will revolutionize health and well-being

22
remaining days
Target
€1.000.000
Invested
107.1%

MgShell

flag

Facilitating chronic eye treatment with a new controlled drug release device

22
remaining days
Target
€650.000
Invested
77.3%

VB Devices

flag

VB Devices automates sclerotherapy with VARIXIO, improving safety, efficacy and consistency of treatment.

22
remaining days
Target
€2.300.000
Invested
101.6%

OxyPrem AG

flag

OxyPrem's sensors help to protect prematurely-born children from brain damage and life-long disabilities.

25
remaining days
Target
€700.000
Invested
40.8%

VERIGRAFT

flag

VERIGRAFT pioneers natural personalized tissue therapies to cure severe and chronic diseases

Successfully closed!
Target
€600.000
Invested
103.7%

Digital Anatomics

flag

We create personalized medical devices for spinal surgery, combining biomechanical engineering and artificial intelligence.

Successfully closed!
Target
€500.000
Invested
114.3%

Arjuna Therapeutics

flag

Arjuna develops a new molecule for metastatic cancers with limited therapeutic options.

Successfully closed!
Target
€2.000.000
Invested
110.6%

Pharmamel

flag

Development of new melatonin-based drugs for sepsis, inflammatory, and viral diseases.

Successfully closed!
Target
€750.000
Invested
113.4%

EktaH

flag

EktaH creates new therapeutic solutions to combat overweight and obesity globally.

Successfully closed!
Target
€1.200.000
Invested
110.2%

Hemerion

flag

Hemerion develops unique light-based therapies to extend and save lives of cancer patients.

Biotech investments: equity funding yields global impact

At Capital Cell fund companies at the cutting edge of science, developing diagnostics, treatments and tools that will transform the future of healthcare.

Through our expert network of more than 3,500 industry professionals, every investment opportunity allows you to have a profound impact on the global health of the future. Only 3% of the companies that are approached by Capital Cell are selected to be funded on our platform, each chosen for its potential to scale globally and the opportunity to earn exceptional returns.

Invest alongside the best science, investment, and social impact institutions.

Lead the health revolution.

For investors

Learn how our smart investments offer you healthy returns.

For life sciences and biotechnology companies

Learn how we support companies seeking investment and our criteria for selection.

Our network of experts

experts are members of the
BioExpert Network

companies have been reviewed
by our experts

BioExpert Network, the independent network of experts

The cornerstone of our evaluation process is the BioExpert Network (BEN), a community of over 3,500 experts in life sciences, health, biotechnology and medicine. The collective wisdom of these highly qualified professionals ensures that only the best biotech investment opportunities make it to our platform.

Alira Health, consulting in health and innovation

Every company that launches a campaign with Capital Cell goes through a thorough maturity assessment with Alira Health, who check that the company understands the regulatory and market access needs and is well prepared at this stage for the coming investment rounds.

Elion, intellectual property
agency

More than 30 institutions and companies already trust Elion for their intellectual property managament, including CSIC, GMV Aerospace & Defence, Tecnalia, Verisure, Sword Health, Venvirotech and the Universities of Liverpool, Complutense de Madrid, Malaga and Galway. 

Success stories we're proud of

Bionure - now Accure Therapeutics - raised €1,200,000 in 2017 and €1,337,000 in 2019 to develop an innovative multiple sclerosis drug.

Vytrus went public through an IPO, giving investors a success with its innovative production of plant cell cultures.

GoodGut's diagnostic and therapeutic technology for digestive diseases continues development and commercialization after its sale to HIPRA.